Reduced cerebrospinal fluid BACE1 activity in multiple sclerosis

Abstract

Background

Cell and animal experiments have shown that β-site APP-cleaving enzyme 1 (BACE1) may be involved in myelination.

Objective

Here, we assess the association of cerebrospinal fluid (CSF) BACE1 activity with multiple sclerosis (MS).

Methods

BACE1 activity and levels of secreted amyloid precursor protein (APP) and amyloid-β (Aβ) isoforms were analyzed in CSF from 100 patients with MS and 114 neurologically healthy controls. Patients with systemic lupus erythematosus (SLE), 26 with and 41 without cerebral engagement, were also included to enable comparisons with regards to another autoimmune disease. A subset of patients with MS and controls underwent a second lumbar puncture after 10 years.

Results

MS patients had lower CSF BACE1 activity than controls (P = 0.03) and patients with cerebral SLE (P < 0.001). Patients with cerebral SLE had higher BACE1 activity than any other group (P < 0.05 for all comparisons). BACE1 activity correlated with the different amyloid markers in all study groups. BACE1 activity decreased over 10 years in the MS group (P = 0.039) and correlated weakly with clinical disease severity scores in an inverse manner.

Conclusions

These results suggest an involvement of BACE1 in the MS disease process.

Keywords

BACE1 cerebrospinal fluid multiple sclerosis myelination neuroinflammation systemic lupus erythematosus

Get full access to this article

View all access options for this article.

References

1 Owens T . The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 2003; 16: 259–265.

2 Chang A Tourtellotte WW Rudick R Trapp BD . Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346: 165–173.

3 Hussain I Powell D Howlett DR . Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 1999; 14: 419–427.

4 Sinha S Anderson JP Barbour R . Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 1999; 402: 537–540.

5 Vassar R Bennett BD Babu-Khan S . Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–741.

6 Yan R Bienkowski MJ Shuck ME . Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 1999; 402: 533–537.

7 Laird FM Cai H Savonenko AV . BACE1, a major determinant of selective vulnerability of the brain to amyloid-beta amyloidogenesis, is essential for cognitive, emotional, and synaptic functions. J Neurosci 2005; 25: 11693–11709.

8 Roberds SL Anderson J Basi G . BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 2001; 10: 1317–1324.

9 Andreasson U Portelius E Andersson ME Blennow K Zetterberg H . Aspects of beta-amyloid as a biomarker for Alzheimer's disease. Biomark Med 2007; 1: 59–78.

10.

10 Hu X Hicks CW He W . Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 2006; 9: 1520–1525.

11.

11 Willem M Garratt AN Novak B . Control of peripheral nerve myelination by the beta-secretase BACE1. Science 2006; 314: 664–666.

12.

12 Taveggia C Thaker P Petrylak A . Type III neuregulin-1 promotes oligodendrocyte myelination. Glia 2008; 56: 284–293.

13.

13 Poser CM Paty DW Scheinberg L . New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

14.

14 McDonald WI Compston A Edan G . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

15.

15 Anckarsater R Vasic N Jideus L . Cerebrospinal fluid protein reactions during non-neurological surgery. Acta Neurol Scand 2007; 115: 254–259.

16.

16 Hochberg MC . Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

17.

17 Trysberg E Nylen K Rosengren LE Tarkowski A . Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881–2887.

18.

18 Breitbach SA Alexander RW Daltroy LH . Determinants of cognitive performance in systemic lupus erythematosus. J Clin Exp Neuropsychol 1998; 20: 157–166.

19.

19 Wu GX Sankaranarayanan S Tugusheva K . Decrease in age-adjusted cerebrospinal fluid beta-secretase activity in Alzheimer's subjects. Clin Biochem 2008; 41: 986–996.

20.

20 Olsson A Vanderstichele H Andreasen N . Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin Chem 2005; 51: 336–345.

21.

21 Haghighi S Andersen O Oden A Rosengren L . Cerebrospinal fluid markers in MS patients and their healthy siblings. Acta Neurol Scand 2004; 109: 97–99.

22.

22 Malmestrom C Haghighi S Rosengren L Andersen O Lycke J . Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003; 61: 1720–1725.

23.

23 Chen S Velardez MO Warot X . Neuregulin 1-erbB signaling is necessary for normal myelination and sensory function. J Neurosci 2006; 26: 3079–3086.

24.

24 Michailov GV Sereda MW Brinkmann BG . Axonal neuregulin-1 regulates myelin sheath thickness. Science 2004; 304: 700–703.

25.

25 Norgren N Sundström P Svenningsson A Rosengren L Stigbrand T Gunnarsson M . Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004; 63: 1586–1590.

26.

26 Cole SL Vassar R . The Alzheimer's disease Beta-secretase enzyme, BACE1. Mol Neurodegener 2007; 2: 22.

27.

27 Rossner S Sastre M Bourne K Lichtenthaler SF . Transcriptional and translational regulation of BACE1 expression–implications for Alzheimer's disease. Prog Neurobiol 2006; 79: 95–111.

28.

28 Sastre M Dewachter I Rossner S . Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A 2006; 103: 443–448.

29.

29 Bourne KZ Ferrari DC Lange-Dohna C Rossner S Wood TG Perez-Polo JR . Differential regulation of BACE1 promoter activity by nuclear factor-kappaB in neurons and glia upon exposure to beta-amyloid peptides. J Neurosci Res 2007; 85: 1194–1204.

30.

30 Hong HS Hwang EM Sim HJ . Interferon gamma stimulates beta-secretase expression and sAPPbeta production in astrocytes. Biochem Biophys Res Commun 2003; 307: 922–927.

31.

31 Zhang X Zhou K Wang R . Hypoxia-inducible factor 1alpha (HIF-1alpha)-mediated hypoxia increases BACE1 expression and beta-amyloid generation. J Biol Chem 2007; 282: 10873–10880.

32.

32 Tamagno E Guglielmotto M Aragno M . Oxidative stress activates a positive feedback between the gamma- and beta-secretase cleavages of the beta-amyloid precursor protein. J Neurochem 2008; 104: 683–695.

33.

33 Ghribi O Larsen B Schrag M Herman MM . High cholesterol content in neurons increases BACE, beta-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp Neurol 2006; 200: 460–467.

34.

34 Blennow K de Leon MJ Zetterberg H . Alzheimer's disease. Lancet 2006; 368: 387–403.